Antibiotics crisis – will PPPs solve the need for super drugs?

[pullquote type=”right”]“[AMR] is an increasingly serious threat to global public health that requires action across all government sectors and society.” – World Health Organization[/pullquote] It is an alarming fact that AMR (AntiMicrobial Resistance) claims 23,000 Americans lives each year. According to a report commissioned by British Prime Minister David Cameron, AMR could result in 10 million deaths a year by 2050 at a cost of …

Predicting Flu Evolution the Next Step Towards Better Flu Vaccines

  Researchers discover that individual flu strains elicit an antibody response to multiple different flu strains already experienced by a patient A global team of researchers using a new modelling system have discovered that upon infection, patients exhibit immune responses to every strain that the individual has encountered, not just the infecting strain. The strongest responses came from the strains …

Research suggests that vaccinations against rare strains of bird flu would be highly effective against a broad range of influenza viruses

A Universal Flu Vaccine: Could Rare Flu Strains be the Answer?

Research suggests that vaccinations against rare strains of bird flu would be highly effective against a broad range of influenza viruses A study by the Emory Vaccine Centre in Atlanta has found that exposure to rare and uncommon flu strains results in the production of broadly effective antibodies. The study thus begs the question: should the public be vaccinated against …

Chikungunya vaccine candidate causes successful development of antibodies against the virus

Chikungunya Vaccine Candidate Passes Phase I Clinical Trials

Chikungunya vaccine candidate causes successful development of antibodies against the virus Chikungunya, a mosquito borne virus, has recently been responsible for outbreaks in the Caribbean and the Pacific. Although the disease is not usually fatal, it causes similar symptoms to a bad flu: muscle aches, malaise and headaches. However, one of the unique aspects of the virus is that it …

AFFiRiS AG has Presented Phase I Data on The Trial for the First Parkinson's Vaccine Candidate

First Clinical Data of Therapeutic Parkinson’s Vaccine is Encouraging

AFFiRiS AG has Presented Phase I Data on a Trial for the First Parkinson’s Vaccine Candidate On the 31st of July 2014, AFFiRiS AG announced as a press conference the results of their phase I clinical trial for a vaccine against Parkinson’s disease.  The vaccine, PD01A, is a therapy that targets the alpha-synuclein protein, a Parkinson’s target. The Michael J.Fox …

Moving Closer to a Strep Vaccine

Researchers from the University of California have identified a possible solution to the often damaging immune response casued by strep for future strep vaccine Group A Streptococcus (strep) is estimated to cost the US $2 billion annually thanks to lost time and productivity amongst its work force.   Whilst for most, the only symptom of strep will be a painful …

Vaccine Asia Live: Recombinant Lipoimmunogen-based therapeutic HPV Vaccine

Human Papilloma Virus(HPV) is a DNA virus that can cause skin & genital warts as well as cervical and osopharyngeal cancers. In the US, there is an increasing trend in cervical cancer in women and osopharyngeal cancer in men.  To make things worse, there are no treatments available for HPV infection. Thus, HPV vaccines have become the most common mode …

Download: Retroscreen Virology paper on preexisting influenza-specific CD4+ T cells and correlation with disease protection

Retroscreen Virology kindly provided this whitepaper, entitled ‘Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.’ Download the whitepaper here. In the paper, the authors suggest that “protective immunity against influenza virus infection is mediated by neutralizing antibodies, but the precise role of T cells in human influenza immunity is uncertain.” Because of this, they …

Universal flu vaccine: recent discovery

ABC News reported last week that scientists have discovered a potentially powerful new treatment for flu viruses. Researchers at Scripps Research Institute in La Jolla, Calif., and Crucell Vaccine Institute in the Netherlands say they have discovered a human antibody that protects against essentially all influenza A and B strains. Read full story here. The researchers believe the antibody could …

How to establish cost-effective vaccine manufacturing practices in Asia

Achieving cost efficiency is imperative in any manufacturing facility/line, and at World Vaccine Congress Asia 2012 last June, Dr I-Teh Tong, Director of Merck & Co., Inc, Pradip Patel, Vice President & Head Vaccine Manufacturing of Cadila Healthcare, Dr Mats Lundgren, Staff Scientist, R&D of GE Healthcare and Dr G S Reddy, Chief General Manager, Manufacturing of Indian Immunologicals discussed …